Targeting senescent cells to undergo apoptosis (senolytics) or inhibition of senescence-associated secretion phenotype (senomorphics) can prevent or improve aging and age-associated diseases (e.g., atherosclerosis, arthritis, chronic fibrosis and cancer metastasis and therapeutic resistance) [3], and p16INK4, Bcl-2 and HSP90 have been reported to act as senotherapeutic targets [3, 4]. The gene discussed is CDKN2A; the disease is cancer.